The human heart endothelin system: ET-1 synthesis, storage, release and effect

Trends in Pharmacological Sciences

Volumn 21, Issue 9, 2000, Pages 353-359

  Russell, Fraser D ^a   Molenaar, Peter ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; ATRASENTAN; BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; RECEPTOR SUBTYPE; RO 468443; UNCLASSIFIED DRUG;

ENDOTHELIUM CELL; HEART; HEART ARRHYTHMIA; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE; HEART MUSCLE CONTRACTILITY; HEART RIGHT ATRIUM; HEART VENTRICLE HYPERTROPHY; HUMAN; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DENSITY; REVIEW;

ANIMALS; ENDOTHELIN-1; HEART; HUMANS; MYOCARDIAL CONTRACTION; MYOCARDIUM;

EID: 0034283692     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(00)01524-8     Document Type: Review

References (52)

1. Clouthier D.E.et al. Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice. Development. 125:1998;813-824.
2. Plumpton C.et al. Expression of endothelin peptides and mRNA in the human heart. Clin. Sci. 90:1996;37-46.
3. Davenport A.P.et al. Endothelin-converting enzyme in human tissues. Histochem. J. 30:1998;359-374.
4. Mebazaa A.et al. Paracrine effects of endocardial endothelial cells on myocyte contraction mediated via endothelin. Am. J. Physiol. 265:1993;H1841-H1846.
5. Tonnessen T.et al. Alterations in plasma endothelin during passage through the left heart chambers before and after brief myocardial ischaemia. Cardiovasc. Res. 27:1993;2160-2163.
6. Wagner O.F.et al. Polar secretion of endothelin-1 by cultured endothelial cells. J. Biol. Chem. 267:1992;16066-16068.
7. Mebazza A.et al. Potential paracrine role of the pericardium in the regulation of cardiac function. Cardiovasc. Res. 40:1998;332-342.
8. Fukuchi M., Giaid A. Expression of endothelin-1 and endothelin-converting enzyme-1 mRNAs and proteins in failing human hearts. J. Cardiovasc. Pharmacol. 31(Suppl. 1):1998;S421-S423.
9. Russell F.D., Davenport A.P. Secretory pathways in endothelin synthesis. Br. J. Pharmacol. 126:1999;391-398.
10. Russell F.D.et al. Human endothelial cell storage granules. A novel intracellular site for isoforms of the endothelin-converting enzyme. Circ. Res. 83:1998;314-321.
11. Pönicke K.et al. Endothelin receptors in the failing and nonfailing human heart. Circulation. 97:1998;744-751.
12. Bax W.A.et al. Endothelin receptors in the human coronary artery, ventricle and atrium. A quantitative autoradiographic analysis. Naunyn-Schmiedeberg's Arch. Pharmacol. 348:1993;403-410.
13. Molenaar P.et al. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ. Res. 72:1993;526-538.
14. Pieske B.et al. Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium. Circulation. 99:1999;1802-1809.
15. B selective ligands in human and rat heart. Br. J. Pharmacol. 119:1996;631-636.
16. Serneri G.G.N.et al. Selective upregulation of cardiac endothelin system in patients with ischemic but not idiopathic dilated cardiomyopathy. Endothelin-1 system in the human failing heart. Circulation. 86:2000;377-385.
17. Burrell K.M.et al. Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: blockade with SB 209670. J. Pharmacol. Exp. Ther. 292:2000;449-459.
18. 125I]endothelin-1 in humans, pigs, and rats: functional relevance in humans. J. Cardiovasc. Pharmacol. 13(Suppl. 5):1989;S166-S170.
19. Zerkowski H-R.et al. Comparison of the positive inotropic effects of serotonin, histamine, angiotensin II, endothelin and isoprenaline in the isolated human right atrium. Naunyn-Schmiedeberg's Arch. Pharmacol. 347:1993;347-352.
20. Meyer M.et al. Influence of endothelin 1 on human atrial myocardium - myocardial function and subcellular pathways. Basic Res. Cardiol. 91:1996;86-93.
21. Hay W.P.et al. Endothelin receptors and calcium translocation pathways in human airways. Naunyn-Schmiedeberg's Arch. Pharmacol. 359:1999;404-410.
22. B specific ligands synergistically antagonize endothelin-1 binding to an atypical endothelin receptor in primary rat astrocytes. J. Neurochem. 70:1998;473-482.
23. Goldberg A.T.et al. Endothelin receptor pathway in human left ventricular myocytes: relation to contractility. Ann. Thorac. Surg. 69:2000;711-716.
24. 2-adrenergic receptors hastens relaxation and mediates phosphorylation of phospholamban, troponin I, and C-protein in ventricular myocardium from patients with terminal heart failure. Circulation. 99:1999;65-72.
25. A receptor antagonist. Circulation. 101:2000;142-147.
26. A-receptors couple to inositol phosphate formation and inhibition of adenylate cyclase in human right atrium. J. Cardiovasc. Pharmacol. 23:1994;344-347.
27. Erdbrügger W.et al. Protein kinase C isoenzymes in rat and human cardiovascular tissues. Br. J. Pharmacol. 120:1997;177-186.
28. Kalman J.M.et al. Atrial fibrillation after coronary artery bypass grafting is associated with sympathetic activation. Ann. Thorac. Surg. 60:1995;1709-1715.
29. Tuinenburg A.E.et al. Comparison of plasma neurohormones in congestive heart failure patients with atrial fibrillation versus patients with sinus rhythm. Am. J. Cardiol. 15:1998;1207-1210.
30. Sakai S.et al. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature. 384:1996;353-355.
31. Mulder P.et al. Role of endogenous endothelin in chronic heart failure. Effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation. 96:1997;1976-1982.
32. Mishima T.et al. Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure. J. Am. Coll. Cardiol. 35:2000;222-229.
33. Hasegawa K.et al. Endothelin-1 and its receptor in hypertrophic cardiomyopathy. Hypertension. 27:1996;259-264.
34. Serneri G.G.N.et al. Cardiac growth factors in human hypertrophy. Relations with myocardial contractility and wall stress. Circ. Res. 85:1999;57-67.
35. Shubeita H.E.et al. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy. J. Biol. Chem. 265:1990;20555-20562.
36. 2+/calmodulin-dependent kinase II and calcineurin play critical roles in endothelin-1-induced cardiomyocyte hypertrophy. J. Biol. Chem. 275:2000;15239-15245.
37. Takeishi Y.et al. Transgenic overexpression of constitutively active protein kinase C ε causes concentric cardiac hypertrophy. Circ. Res. 86:2000;1218-1223.
38. Rybin V.O.et al. Activated protein kinase C isoforms target to cardiomyocyte caveolae. Stimulation of local protein phosphorylation. Circ. Res. 84:1999;980-988.
39. Clerk A.et al. Stimulation of the p38 mitogen-activated protein kinase pathway in neonatal rat ventricular myocytes by the G protein-coupled receptor agonists, endothelin-1 and phenylephrine: a role in cardiac myocyte hypertrophy? J. Cell. Biol. 142:1998;523-535.
40. Sugden P.H. Signaling in myocardial hypertrophy. Life after calcineurin? Circ. Res. 84:1999;633-646.
41. Molkentin J.D.et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 93:1998;215-228.
42. Olson E.N., Molkentin J.D. Prevention of cardiac hypertrophy by calcineurin inhibition. Hope or hype? Circ. Res. 84:1999;623-632.
43. Luo C.et al. Interaction of calcineurin with a domain of the transcription factor NFAT1 that controls nuclear import. Proc. Natl. Acad. Sci. U. S. A. 93:1996;8907-8912.
44. Zolk O.et al. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. Circulation. 99:1999;2118-2123.
45. Beyermann B.et al. Increased endothelin-1 peptide concentrations in failing human myocardium. Eur. Heart J. 18(Suppl.):1997;39.
46. Love M.P., McMurray J.J.V. Endothelin in congestive heart failure. Basic Res. Cardiol. 91(Suppl. 1):1996;21-29.
47. Pacher R.et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J. Am. Coll. Cardiol. 27:1996;633-641.
48. Clavell A.et al. Angiotensin converting enzyme inhibition modulates endogenous endothelin in chronic canine thoracic inferior vena caval constriction. J. Clin. Invest. 97:1996;1286-1292.
49. Sütsch G.et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation. 98:1998;2262-2268.
50. A receptor blockade in patients with congestive heart failure. J. Am. Coll. Cardiol. 35:2000;1745-1752.
51. Strachan F.E.et al. Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension. 33:1999;581-585.
52. Canale E.D.et al. Handbook of Microscopic Anatomy. Oksche A., Vollrath L. Volume II/7: Cardiac muscle. 1986;Springer-Verlag.